» Articles » PMID: 11294577

Intestinal Permeability Tests in Coeliac Disease

Overview
Journal Clin Lab
Specialty Pathology
Date 2001 Apr 11
PMID 11294577
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Intestinal permeability tests have been used to screen for a wide range of small intestinal diseases, including coeliac disease and enteric infections. Several probe molecules have been used to investigate intestinal permeability including monosaccharides, disaccharides, 51Cr-EDTA and polyethyleneglycol. While many factors may affect intestinal permeability tests, the use of two probe molecules, for example, lactulose and mannitol, and the expression of the result as a ratio minimises the effects of these extraneous factors. Rendering the test solution hyperosmolar was also found to increase the sensitivity of the test in detecting coeliac disease. Intestinal permeability is characteristically elevated in untreated coeliac disease, with a sensitivity of up to 96% for the dual sugar techniques. The reason for this is a consistent increase in the absorption of lactulose (via the paracellular route) due to increased "leakiness" of the intestine and a reduction in the absorption of mannitol (via the transcellular route) due to a reduction in surface area as a result of villous atrophy. The intestinal permeability test allows subjects to be selected for jejunal biopsy in whom the clinical features are compatible with coeliac disease and in timing a follow-up biopsy. It has been postulated that raised intestinal permeability may be involved in the pathogenesis of coeliac disease. Recently, serum measurements of the probe molecules may have a valuable role, particularly in paediatric patients. Sucrose permeability has also been proposed as an accurate marker of adult coeliac disease and shows promise as a noninvasive test.

Citing Articles

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.

Salem F, Nimavardi A, Mudunuru J, Tompson D, Bloomer J, Turner D CPT Pharmacometrics Syst Pharmacol. 2023; 12(6):808-820.

PMID: 36855819 PMC: 10272307. DOI: 10.1002/psp4.12954.


Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease.

Biolato M, Manca F, Marrone G, Cefalo C, Racco S, Miggiano G World J Gastroenterol. 2019; 25(4):509-520.

PMID: 30700946 PMC: 6350174. DOI: 10.3748/wjg.v25.i4.509.


Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer.

Ierardi E, Losurdo G, Piscitelli D, Giorgio F, Amoruso A, Iannone A Gastroenterol Hepatol Bed Bench. 2018; 11(3):203-208.

PMID: 30013743 PMC: 6040034.


Real-time Measurement of Epithelial Barrier Permeability in Human Intestinal Organoids.

Hill D, Huang S, Tsai Y, Spence J, Young V J Vis Exp. 2017; (130).

PMID: 29286482 PMC: 5755602. DOI: 10.3791/56960.


Role of corticotrophin releasing hormone in cerebral infarction-related gastrointestinal barrier dysfunction.

Liu Y, Qi Z, Guo S, Wang Z, Yu X, Ma S World J Emerg Med. 2014; 2(1):59-65.

PMID: 25214985 PMC: 4129739.